Stopping Ozempic Raises Cardiovascular Risk by 22 Percent
A VA study of 600,000 patients found that quitting GLP-1 drugs for two years erased all cardiovascular benefits and then some.
The news. The narrative. The timeline.
Bureau: Chicago
A VA study of 600,000 patients found that quitting GLP-1 drugs for two years erased all cardiovascular benefits and then some.
A Lancet study projects that rising temperatures will make people too hot to exercise, contributing to 520,000 additional premature deaths annually by 2050.
One in seven American adults now takes or has taken a GLP-1 drug — and the behavioral, social, and identity shifts are outrunning the clinical data.